Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Musculoskeletal Organoid Research Center, Shanghai University, Shanghai, 200444, China.
Theranostics. 2022 Sep 11;12(15):6576-6594. doi: 10.7150/thno.78034. eCollection 2022.
Bone and soft tissue tumors are complex mesenchymal neoplasms that seriously endanger human health. Over the past decade, the relationship between microorganisms and human health and diseases is getting more attention. The extracellular vesicles derived from bacteria have been shown to regulate bacterial-host cell communication by transferring their contents, including nucleic acids, proteins, metabolites, lipopolysaccharides, and peptidoglycans. Bacteria extracellular vesicles (BEVs) are promising lipid-bilayer nanocarriers for the treatment of many diseases due to their low toxicity, drug loading capacity, ease of modification and industrialization. Specially, BEVs-based cancer therapy has attracted much attention because of their ability to effectively stimulate immune responses. In this review, we provide an overview of the biogenesis, composition, isolation, classification, and internalization of BEVs. We then comprehensively summarize the sources of BEVs in cancer therapy and the BEVs-related cancer treatment strategies. We further highlight the great potential of BEVs in bone and soft tissue tumors. Finally, we conclude the major advantages and challenges of BEVs-based cancer therapy. We believe that the comprehensive understanding of BEVs in the field of cancer therapy will generate innovative solutions to bone and soft tissue tumors and achieve clinical applications.
骨与软组织肿瘤是严重危害人类健康的复杂间叶性肿瘤。近十年来,微生物与人类健康和疾病的关系越来越受到关注。细菌来源的细胞外囊泡通过转移其内容物(包括核酸、蛋白质、代谢物、脂多糖和肽聚糖)来调节细菌-宿主细胞通讯。由于细菌细胞外囊泡 (BEVs) 的低毒性、载药能力、易于修饰和工业化等特点,它们是很有前途的脂质双层纳米载体,可用于治疗许多疾病。特别是,由于其有效刺激免疫反应的能力,BEVs 为癌症治疗吸引了广泛关注。在本综述中,我们概述了 BEVs 的生物发生、组成、分离、分类和内化。然后,我们全面总结了 BEVs 在癌症治疗中的来源以及 BEVs 相关的癌症治疗策略。我们进一步强调了 BEVs 在骨与软组织肿瘤中的巨大潜力。最后,我们总结了 BEVs 为基础的癌症治疗的主要优势和挑战。我们相信,对癌症治疗领域 BEVs 的全面了解将为骨与软组织肿瘤产生创新的解决方案,并实现临床应用。
Microb Pathog. 2023-10
J Extracell Vesicles. 2024-10
J Control Release. 2023-12
Cytokine Growth Factor Rev. 2023-10
Life (Basel). 2025-7-14
Cancers (Basel). 2025-5-26
Extracell Vesicles Circ Nucl Acids. 2025-1-17
Mater Today Bio. 2025-1-3
J Microbiol Biotechnol. 2024-12-17
Theranostics. 2025-1-1
J Nanobiotechnology. 2024-11-6
Theranostics. 2022
Bioact Mater. 2022-5-27
Adv Drug Deliv Rev. 2022-6
Adv Drug Deliv Rev. 2022-6
Front Bioeng Biotechnol. 2022-4-1
Bioact Mater. 2022-2-5